FR2525603A1 - Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique - Google Patents

Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique Download PDF

Info

Publication number: FR2525603A1
Authority: FR; France
Prior art keywords: spiro; formula; salt; dione; isoquinoline
Prior art date: 1982-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

FR8207203A

Other languages

English (en)

French (fr)

Other versions

FR2525603B1 (2

Inventor

Charles Malen

Jean-Louis Peglion

Jacques Duhault

Michele Boulanger

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ADIR SARL

Original Assignee

ADIR SARL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-27

Filing date

1982-04-27

Publication date

1983-10-28

1982-04-27 Application filed by ADIR SARL filed Critical ADIR SARL

1982-04-27 Priority to FR8207203A priority Critical patent/FR2525603A1/fr

1983-04-08 Priority to AT0125383A priority patent/ATA125383A/de

1983-04-25 Priority to LU84770A priority patent/LU84770A1/fr

1983-04-25 Priority to DD83250187A priority patent/DD209833A5/de

1983-04-26 Priority to BE0/210633A priority patent/BE896572A/fr

1983-04-26 Priority to NO831473A priority patent/NO831473L/no

1983-04-26 Priority to IL68497A priority patent/IL68497A0/xx

1983-04-26 Priority to SE8302347A priority patent/SE8302347L/xx

1983-04-26 Priority to KR1019830001753A priority patent/KR840004428A/ko

1983-04-26 Priority to PT76595A priority patent/PT76595B/pt

1983-04-26 Priority to NL8301476A priority patent/NL8301476A/nl

1983-04-26 Priority to JP58073687A priority patent/JPS5910584A/ja

1983-04-26 Priority to GR71214A priority patent/GR78481B/el

1983-04-26 Priority to DK183583A priority patent/DK183583A/da

1983-04-26 Priority to ZA832927A priority patent/ZA832927B/xx

1983-04-26 Priority to AU13953/83A priority patent/AU1395383A/en

1983-04-26 Priority to IT48155/83A priority patent/IT1167123B/it

1983-04-27 Priority to ES521895A priority patent/ES521895A0/es

1983-04-27 Priority to GB08311508A priority patent/GB2133401B/en

1983-04-27 Priority to OA57984A priority patent/OA07412A/xx

1983-04-27 Priority to MA20003A priority patent/MA19783A1/fr

1983-04-27 Priority to DE19833315106 priority patent/DE3315106A1/de

1983-10-28 Publication of FR2525603A1 publication Critical patent/FR2525603A1/fr

1984-09-14 Application granted granted Critical

1984-09-14 Publication of FR2525603B1 publication Critical patent/FR2525603B1/fr

Status Granted legal-status Critical Current

Links

238000002360 preparation method Methods 0.000 title claims description 5
230000001225 therapeutic effect Effects 0.000 title description 3
150000003839 salts Chemical class 0.000 claims abstract description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
239000001257 hydrogen Substances 0.000 claims abstract description 5
230000003287 optical effect Effects 0.000 claims abstract description 4
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 24
-1 p-toluenesulfonyl Chemical group 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 8
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
QAHZIGHCEBUNGT-QMGFNSACSA-N (5r,6s,7s,8r,9r)-6,7,8-trihydroxy-9-(hydroxymethyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)C[C@]11C(=O)NC(=O)N1 QAHZIGHCEBUNGT-QMGFNSACSA-N 0.000 claims description 4
125000002252 acyl group Chemical group 0.000 claims description 3
229910021529 ammonia Inorganic materials 0.000 claims description 3
150000003863 ammonium salts Chemical class 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
229910052783 alkali metal Inorganic materials 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
238000009833 condensation Methods 0.000 claims description 2
230000005494 condensation Effects 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
CHZPJUSFUDUEMZ-UHFFFAOYSA-M 3-acetylbenzoate Chemical compound CC(=O)C1=CC=CC(C([O-])=O)=C1 CHZPJUSFUDUEMZ-UHFFFAOYSA-M 0.000 claims 1
150000007513 acids Chemical class 0.000 claims 1
150000001768 cations Chemical class 0.000 claims 1
150000004820 halides Chemical class 0.000 claims 1
150000007529 inorganic bases Chemical class 0.000 claims 1
231100000252 nontoxic Toxicity 0.000 claims 1
230000003000 nontoxic effect Effects 0.000 claims 1
150000007530 organic bases Chemical class 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical group [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 abstract 1
150000002367 halogens Chemical group 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
229940126601 medicinal product Drugs 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
239000000047 product Substances 0.000 description 9
150000002576 ketones Chemical class 0.000 description 8
239000000243 solution Substances 0.000 description 8
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical class C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000011282 treatment Methods 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
102000016912 Aldehyde Reductase Human genes 0.000 description 4
108010053754 Aldehyde reductase Proteins 0.000 description 4
101100352919 Caenorhabditis elegans ppm-2 gene Proteins 0.000 description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
239000008103 glucose Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
239000002585 base Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
210000000695 crystalline len Anatomy 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
206010007749 Cataract diabetic Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
201000007025 diabetic cataract Diseases 0.000 description 2
150000005690 diesters Chemical class 0.000 description 2
230000000694 effects Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000002798 polar solvent Substances 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000005057 refrigeration Methods 0.000 description 2
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
NJHWVBIQAKXVIY-UHFFFAOYSA-N 1-(6-chloro-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound ClC1=CC=C2CN(C(=O)C)CCC2=C1 NJHWVBIQAKXVIY-UHFFFAOYSA-N 0.000 description 1
AYQMNFRCBKOMIA-UHFFFAOYSA-N 1-benzazepin-2-one Chemical class O=C1C=CC=C2C=CC=CC2=N1 AYQMNFRCBKOMIA-UHFFFAOYSA-N 0.000 description 1
PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 1
KGSVNOLLROCJQM-UHFFFAOYSA-N 2-(benzylamino)acetic acid Chemical compound OC(=O)CNCC1=CC=CC=C1 KGSVNOLLROCJQM-UHFFFAOYSA-N 0.000 description 1
YSZHSZDDIWNDEI-UHFFFAOYSA-N 2-(bromomethyl)-5-chlorobenzoic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1CBr YSZHSZDDIWNDEI-UHFFFAOYSA-N 0.000 description 1
ROWPRXGFODHMBU-UHFFFAOYSA-N 2-benzyl-6-chloro-1,3-dihydroisoquinolin-4-one Chemical compound C1C(=O)C2=CC(Cl)=CC=C2CN1CC1=CC=CC=C1 ROWPRXGFODHMBU-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
102000014824 Crystallins Human genes 0.000 description 1
108010064003 Crystallins Proteins 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
102100034866 Kallikrein-6 Human genes 0.000 description 1
HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 1
241000212342 Sium Species 0.000 description 1
238000007059 Strecker synthesis reaction Methods 0.000 description 1
208000014306 Trophic disease Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001312 aldohexoses Chemical class 0.000 description 1
150000001323 aldoses Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
235000012501 ammonium carbonate Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000006264 debenzylation reaction Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002085 enols Chemical group 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical class CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
229940091173 hydantoin Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000002075 main ingredient Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000007830 nerve conduction Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
239000006187 pill Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
210000005077 saccule Anatomy 0.000 description 1
HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
101150035983 str1 gene Proteins 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
210000002268 wool Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

FR8207203A 1982-04-27 1982-04-27 Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique Granted FR2525603A1 (fr)

Priority Applications (22)

Application Number	Priority Date	Filing Date	Title
FR8207203A FR2525603A1 (fr)	1982-04-27	1982-04-27	Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique
AT0125383A ATA125383A (de)	1982-04-27	1983-04-08	Verfahren zur herstellung von neuen benzoazacycloalkyl-spiro-imidazolidinen
DD83250187A DD209833A5 (de)	1982-04-27	1983-04-25	Verfahren zur herstellung von benzoazacycloalkyl-spiro-imidazolidinen
LU84770A LU84770A1 (fr)	1982-04-27	1983-04-25	Benzoazacycloalkyl-spiro-imidazolidines,leur preparation et leur application en therapeutique
AU13953/83A AU1395383A (en)	1982-04-27	1983-04-26	Benzoazacycloalkyl-spiro-imidazolidines
IL68497A IL68497A0 (en)	1982-04-27	1983-04-26	Benzoazacycloalkyl-spiro-imidazolidines,their preparation and pharmaceutical compositions containing them
SE8302347A SE8302347L (sv)	1982-04-27	1983-04-26	Bensoazacykloalkyl-spiro-imidazolidiner, framstellning derav och farmaceutiska kompositioner innehallande dem
KR1019830001753A KR840004428A (ko)	1982-04-27	1983-04-26	벤조 아자시클로 알킬-스피로-이미다졸리딘의 제조방법
PT76595A PT76595B (fr)	1982-04-27	1983-04-26	Procede de preparation de benzoazacycloalkyl-spiro-imidazolidines
NL8301476A NL8301476A (nl)	1982-04-27	1983-04-26	Benzoazacycloalkylspiroimidazolidines, hun bereiding en farmaceutische samenstellingen welke deze bevatten.
BE0/210633A BE896572A (fr)	1982-04-27	1983-04-26	Benzoazacycloalkyl-spiro-imidazolidines leur preparation et leur application en therapeutique
GR71214A GR78481B (2)	1982-04-27	1983-04-26
DK183583A DK183583A (da)	1982-04-27	1983-04-26	Fremgangsmaade til fremstilling af benzoazacycloalkyl-spiro-imidazolidiner
ZA832927A ZA832927B (en)	1982-04-27	1983-04-26	Benzoazacycloalkyl-spiro-imidazolidines,their preparation and compositions containing them
NO831473A NO831473L (no)	1982-04-27	1983-04-26	Fremgangsmaate ved fremstilling av benzoazacykloalkyl-spiro-imidazolidiner
IT48155/83A IT1167123B (it)	1982-04-27	1983-04-26	Benzoazacicloalchilspiro-imidazolidine,procedimento per prepararle e composizioni farmaceutiche che le contengono
JP58073687A JPS5910584A (ja)	1982-04-27	1983-04-26	イミダゾリジン誘導体
ES521895A ES521895A0 (es)	1982-04-27	1983-04-27	Procedimiento de preparacion de benzoazacicloalquil-espiroimidazolidina, asi como de sus sales obtenidas con bases minerales u organicas farmaceuticamente aceptables.
GB08311508A GB2133401B (en)	1982-04-27	1983-04-27	Benzoazacycloalkyl-spiro-imidazolidines
OA57984A OA07412A (fr)	1982-04-27	1983-04-27	Benzoazacycloalhyl-spiro-imidazolidines leur préparation et leur application en thérapeutique.
MA20003A MA19783A1 (fr)	1982-04-27	1983-04-27	Procede de preparation de benzoazacycloalkyl-spiro-imidazolidines.
DE19833315106 DE3315106A1 (de)	1982-04-27	1983-04-27	Benzoazacycloalkyl-spiro-imidazolidine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8207203A FR2525603A1 (fr)	1982-04-27	1982-04-27	Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique

Publications (2)

Publication Number	Publication Date
FR2525603A1 true FR2525603A1 (fr)	1983-10-28
FR2525603B1 FR2525603B1 (2)	1984-09-14

Family

ID=9273425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR8207203A Granted FR2525603A1 (fr)	1982-04-27	1982-04-27	Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique

Country Status (22)

Country	Link
JP (1)	JPS5910584A (2)
KR (1)	KR840004428A (2)
AT (1)	ATA125383A (2)
AU (1)	AU1395383A (2)
BE (1)	BE896572A (2)
DD (1)	DD209833A5 (2)
DE (1)	DE3315106A1 (2)
DK (1)	DK183583A (2)
ES (1)	ES521895A0 (2)
FR (1)	FR2525603A1 (2)
GB (1)	GB2133401B (2)
GR (1)	GR78481B (2)
IL (1)	IL68497A0 (2)
IT (1)	IT1167123B (2)
LU (1)	LU84770A1 (2)
MA (1)	MA19783A1 (2)
NL (1)	NL8301476A (2)
NO (1)	NO831473L (2)
OA (1)	OA07412A (2)
PT (1)	PT76595B (2)
SE (1)	SE8302347L (2)
ZA (1)	ZA832927B (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4927831A (en) *	1988-10-20	1990-05-22	American Home Products	Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
AU617541B2 (en) *	1988-10-20	1991-11-28	Wyeth	Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
HUE028976T2 (en)	2003-06-17	2017-02-28	Arena Pharm Inc	8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
CN1805938B (zh)	2003-06-17	2010-06-16	艾尼纳制药公司	用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
SI1838677T1 (sl)	2004-12-21	2010-01-29	Arena Pharm Inc	Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida
SG158168A1 (en)	2004-12-23	2010-01-29	Arena Pharm Inc	5ht2c receptor modulator compositions and methods of use
EP2471779A1 (en)	2006-04-03	2012-07-04	Arena Pharmaceuticals, Inc.	Process for the resolution of a mixture of (R)- and (S)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US8299241B2 (en)	2006-12-05	2012-10-30	Arena Pharmaceuticals, Inc.	Processes for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates thereof
CN102015591B (zh)	2008-03-04	2014-01-29	艾尼纳制药公司	制备与5-ht2c激动剂(r)-8-氯-1-甲基-2，3，4，5-四氢-1h-3-苯并氮杂卓相关的中间体的方法
US8952197B2 (en)	2009-06-18	2015-02-10	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-HT2C receptor agonists
KR20130112848A (ko)	2010-06-02	2013-10-14	아레나 파마슈티칼스, 인크.	5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
JP2013536859A (ja)	2010-09-01	2013-09-26	アリーナファーマシューティカルズ，インコーポレイテッド	５−ｈｔ２ｃアゴニストの非吸湿性塩
KR20140091458A (ko)	2010-09-01	2014-07-21	아레나 파마슈티칼스, 인크.	신장 손상을 갖는 개체에 대한 로카세린의 투여
EP3485878A1 (en)	2010-09-01	2019-05-22	Arena Pharmaceuticals, Inc.	Modified-release dosage forms of 5-ht2c agonists useful for weight management
KR20130138770A (ko)	2010-09-01	2013-12-19	아레나 파마슈티칼스, 인크.	광학적으로 활성 산을 갖는 로르카세린의 염
WO2014058441A1 (en)	2012-10-09	2014-04-17	Arena Pharmaceuticals, Inc.	Method of weight management

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0021704A1 (en) *	1979-06-13	1981-01-07	Pfizer Inc.	Spiro-hydantoin derivatives, process for their preparation and pharmaceutical compositions thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4209630A (en) *	1976-10-18	1980-06-24	Pfizer Inc.	Hydantoin derivatives as therapeutic agents

1982
- 1982-04-27 FR FR8207203A patent/FR2525603A1/fr active Granted
1983
- 1983-04-08 AT AT0125383A patent/ATA125383A/de not_active IP Right Cessation
- 1983-04-25 DD DD83250187A patent/DD209833A5/de unknown
- 1983-04-25 LU LU84770A patent/LU84770A1/fr unknown
- 1983-04-26 BE BE0/210633A patent/BE896572A/fr not_active IP Right Cessation
- 1983-04-26 NO NO831473A patent/NO831473L/no unknown
- 1983-04-26 GR GR71214A patent/GR78481B/el unknown
- 1983-04-26 DK DK183583A patent/DK183583A/da not_active Application Discontinuation
- 1983-04-26 PT PT76595A patent/PT76595B/pt unknown
- 1983-04-26 IT IT48155/83A patent/IT1167123B/it active
- 1983-04-26 AU AU13953/83A patent/AU1395383A/en not_active Abandoned
- 1983-04-26 SE SE8302347A patent/SE8302347L/xx not_active Application Discontinuation
- 1983-04-26 KR KR1019830001753A patent/KR840004428A/ko not_active Withdrawn
- 1983-04-26 IL IL68497A patent/IL68497A0/xx unknown
- 1983-04-26 NL NL8301476A patent/NL8301476A/nl not_active Application Discontinuation
- 1983-04-26 JP JP58073687A patent/JPS5910584A/ja active Pending
- 1983-04-26 ZA ZA832927A patent/ZA832927B/xx unknown
- 1983-04-27 ES ES521895A patent/ES521895A0/es active Granted
- 1983-04-27 MA MA20003A patent/MA19783A1/fr unknown
- 1983-04-27 DE DE19833315106 patent/DE3315106A1/de not_active Withdrawn
- 1983-04-27 GB GB08311508A patent/GB2133401B/en not_active Expired
- 1983-04-27 OA OA57984A patent/OA07412A/xx unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0021704A1 (en) *	1979-06-13	1981-01-07	Pfizer Inc.	Spiro-hydantoin derivatives, process for their preparation and pharmaceutical compositions thereof

Also Published As

Publication number	Publication date
GB8311508D0 (en)	1983-06-02
ATA125383A (de)	1986-05-15
FR2525603B1 (2)	1984-09-14
NL8301476A (nl)	1983-11-16
DE3315106A1 (de)	1983-11-03
PT76595B (fr)	1986-01-21
KR840004428A (ko)	1984-10-15
ES8405796A1 (es)	1984-06-16
GB2133401A (en)	1984-07-25
GB2133401B (en)	1985-10-23
ZA832927B (en)	1984-06-27
SE8302347L (sv)	1983-10-28
PT76595A (fr)	1983-05-01
SE8302347D0 (sv)	1983-04-26
IT1167123B (it)	1987-05-13
NO831473L (no)	1983-10-28
MA19783A1 (fr)	1983-12-31
DK183583A (da)	1983-10-28
AU1395383A (en)	1983-11-03
JPS5910584A (ja)	1984-01-20
DK183583D0 (da)	1983-04-26
IT8348155A0 (it)	1983-04-26
OA07412A (fr)	1984-11-30
DD209833A5 (de)	1984-05-23
ES521895A0 (es)	1984-06-16
IL68497A0 (en)	1983-07-31
LU84770A1 (fr)	1984-11-28
BE896572A (fr)	1983-10-26
GR78481B (2)	1984-09-27

Legal Events

Date	Code	Title	Description
1991-03-01	ST	Notification of lapse

Publication	Publication Date	Title
FR2525603A1 (fr)	1983-10-28	Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique
US4200642A (en)	1980-04-29	Spiro-oxazolidindiones
EP0281459A1 (fr)	1988-09-07	Enantiomère dextrogyre de l'alpha-(tétrahydro-4,5,6,7 thiéno (3,2-c)pyridyl-5) (chloro-2 phényl)-acétate de méthyle, son procédé de préparation et les compositions pharmaceutiques le renfermant
WO1985004652A1 (fr)	1985-10-24	Derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications
CA2176668C (fr)	2001-11-20	Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US4283539A (en)	1981-08-11	Isoquinoline acetic acids
EP0051023A1 (fr)	1982-05-05	Nouveaux composés appartenant à la famille des benzoyl- et alpha-hydroxybenzyl-phényl-osides, leur procédé de préparation et leur application en thérapeutique
FR2620121A1 (fr)	1989-03-10	((pyrimidinyl-2)-aminoalkyl)-1 piperidines, leur preparation et leur application en therapeutique
EP0350403A1 (fr)	1990-01-10	Dérivés de (aza)naphtalènesultame, leurs procédés de préparation et les médicaments les contenant
EP0252823A1 (fr)	1988-01-13	Nouveaux dérivés du 1H, 3H-pyrrolo [1,2-c] thiazole, leur préparation et les compositions pharmaceutiques qui les contiennent
EP0253711A1 (fr)	1988-01-20	Nouveaux dérivés du 1H,3H-Pyrrolo [1,2-c] thiazole, leur préparation et les Compositions pharmaceutiques qui les contiennent
EP0125195B1 (fr)	1987-09-30	Nouveaux acides flavonecarboxyliques-4', leur méthode de préparation et leur application thérapeutique
US4134991A (en)	1979-01-16	Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid
EP0319412B1 (fr)	1992-03-11	Nouveaux dérivés flavonoides pipérazinyl-2 oxo-2 éthylène substitués, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
BE1009852A3 (fr)	1997-10-07	Derives 1-[2(vinyl-substitues)]-3-4-dihydro-5h-2,3-benzodiazepine.
EP0479631A1 (fr)	1992-04-08	Dérivés du spiro [4.5]décane leur procédé de préparation et les compositions pharmaceutiques les renfermant
US4025649A (en)	1977-05-24	Acetic acid derivatives having pharmacological activity and compositions containing the same
EP0004494A1 (fr)	1979-10-03	Nouveaux dérivés de 1,3-dihydro 3-(1-(2-(2,3-dihydro 1,4-benzo-dioxin-2-yl)2-hydroxy éthyl)pipéridin-4-yl)2H-indol 2-one, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
FR2643634A1 (fr)	1990-08-31	Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP0074903A2 (fr)	1983-03-23	Dérivés d'amino-2 tétrahydro-1,2,3,4 naphtalène, leur préparation et leur application en thérapeutique
EP0301936A1 (fr)	1989-02-01	Dérivés de pipéridine, leur préparation et leur application en thérapeutique
FR2610932A1 (fr)	1988-08-19	Nouvel acide piperazinecarboxylique, sa preparation et son utilisation comme medicament
JPS61286359A (ja)	1986-12-16	Ｎ−〔〔５−（トリフルオロメチル）−６−メトキシ−１−ナフタレニル〕チオキソメチルまたはカルボニル〕−ｎ−メチルグリシンアミド
EP0427605B1 (fr)	1994-04-27	Nouveaux dérivés de la morpholine, leur procédé de préparation et les compositions pharmaceutiques les renfermant
EP0002401B1 (fr)	1980-12-10	Dérivés de naphtalène, leur préparation et leur application en thérapeutique